Allogene Therapeutics (ALLO) Total Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Total Non-Current Liabilities data on file, last reported at $101.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 9.3% year-over-year to $101.0 million; the trailing twelve-month figure through Mar 2026 stood at $101.0 million (down 9.3% YoY), and the FY2025 full-year result was $107.6 million, down 9.44% from the prior year.
• Total Non-Current Liabilities fell to $101.0 million in Q1 2026, from $107.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $152.9 million in Q1 2023 to a low of $101.0 million in Q1 2026.
• A 5-year average of $124.4 million and a median of $119.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 46.5% in 2022 and decreased 21.65% in 2024, its largest moves.
• Tracing ALLO's Total Non-Current Liabilities over 5 years: stood at $148.8 million in 2022, then fell by 15.74% to $125.4 million in 2023, then declined by 5.31% to $118.8 million in 2024, then dropped by 9.44% to $107.6 million in 2025, then slipped by 6.13% to $101.0 million in 2026.
• Business Quant data shows ALLO's Total Non-Current Liabilities at $101.0 million in Q1 2026, $107.6 million in Q4 2025, and $109.0 million in Q3 2025.